Cargando…

Circulating fibrinogen is a prognostic and predictive biomarker in malignant pleural mesothelioma

BACKGROUND: To investigate the clinical utility of pretreatment plasma fibrinogen levels in malignant pleural mesothelioma (MPM) patients. METHODS: A retrospective multicenter study was performed in histologically proven MPM patients. All fibrinogen levels were measured at the time of diagnosis and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ghanim, B, Hoda, M A, Klikovits, T, Winter, M-P, Alimohammadi, A, Grusch, M, Dome, B, Arns, M, Schenk, P, Jakopovic, M, Samarzija, M, Brcic, L, Filipits, M, Laszlo, V, Klepetko, W, Berger, W, Hegedus, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3929892/ https://www.ncbi.nlm.nih.gov/pubmed/24434429 http://dx.doi.org/10.1038/bjc.2013.815

Ejemplares similares

Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells
por: Hoda, M A, et al.
Publicado: (2012)

Ki67 index is an independent prognostic factor in epithelioid but not in non-epithelioid malignant pleural mesothelioma: a multicenter study
por: Ghanim, B, et al.
Publicado: (2015)

Fibulin-3 levels in malignant pleural mesothelioma are associated with prognosis but not diagnosis
por: Kirschner, Michaela B, et al.
Publicado: (2015)

Prognostic impact of PD-1 and PD-L1 expression in malignant pleural mesothelioma: an international multicenter study
por: Brcic, Luka, et al.
Publicado: (2021)

Circulating FGF18 is decreased in pleural mesothelioma but not correlated with disease prognosis
por: Mosleh, Berta, et al.
Publicado: (2023)

The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma
por: Laszlo, Viktoria, et al.
Publicado: (2018)

Circulating complement component 4d (C4d) correlates with tumor volume, chemotherapeutic response and survival in patients with malignant pleural mesothelioma
por: Klikovits, Thomas, et al.
Publicado: (2017)

Expression of FGFR1–4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity
por: Vlacic, Gregor, et al.
Publicado: (2019)

Management of malignant pleural mesothelioma – part 3: Data from the Austrian Mesothelioma Interest Group (AMIG) database
por: Klikovits, Thomas, et al.
Publicado: (2016)

Management of malignant pleural mesothelioma—part 2: therapeutic approaches: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

Management of malignant pleural mesothelioma – part 1: epidemiology, diagnosis, and staging: Consensus of the Austrian Mesothelioma Interest Group (AMIG)
por: Geltner, Christian, et al.
Publicado: (2016)

Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion
por: Tsuji, S, et al.
Publicado: (2010)

Impact of fibrinogen levels and modified Glasgow prognostic score on survival of stage III/N2 non-small cell lung cancer patients treated with neoadjuvant therapy and radical resection
por: Sinn, Katharina, et al.
Publicado: (2022)

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis
por: Cui, Ai, et al.
Publicado: (2014)

Differential p16/INK4A cyclin-dependent kinase inhibitor expression correlates with chemotherapy efficacy in a cohort of 88 malignant pleural mesothelioma patients
por: Jennings, C J, et al.
Publicado: (2015)

Malignant pleural mesothelioma nodules remodel their surroundings to vascularize and grow
por: Kovacs, Ildiko, et al.
Publicado: (2022)

CD74: a new prognostic factor for patients with malignant pleural mesothelioma
por: Otterstrom, C, et al.
Publicado: (2014)

SV40 associated miRNAs are not detectable in mesotheliomas
por: Gee, G V, et al.
Publicado: (2010)

Overexpression and altered glycosylation of MUC1 in malignant mesothelioma
por: Creaney, J, et al.
Publicado: (2008)

Clinical significance of histologic subtyping of malignant pleural mesothelioma
por: Brcic, Luka, et al.
Publicado: (2020)

A proteomics-based approach identifies secreted protein acidic and rich in cysteine as a prognostic biomarker in malignant pleural mesothelioma
por: Kao, Steven C, et al.
Publicado: (2016)

High circulating activin A level is associated with tumor progression and predicts poor prognosis in lung adenocarcinoma
por: Hoda, Mir Alireza, et al.
Publicado: (2016)

Markers for the non-invasive diagnosis of mesothelioma: a systematic review
por: van der Bij, S, et al.
Publicado: (2011)

The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma
por: Pinato, D J, et al.
Publicado: (2013)

Cisplatin-induced expression of Gb3 enables verotoxin-1 treatment of cisplatin resistance in malignant pleural mesothelioma cells
por: Johansson, D, et al.
Publicado: (2010)

Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin
por: Ries, Alexander, et al.
Publicado: (2023)

Prostaglandin E(2) stimulates progression-related gene expression in early colorectal adenoma cells
por: Mauritz, I, et al.
Publicado: (2006)

Lung Abscess: An Early Complication of Lung Transplantation in a Patient with Cystic Fibrosis
por: Markelić, I., et al.
Publicado: (2017)

The endoplasmic reticulum stress marker CHOP predicts survival in malignant mesothelioma
por: Dalton, L E, et al.
Publicado: (2013)

Corrigendum to ‘Neoadjuvant chemoradiotherapy is superior to chemotherapy alone in surgically treated stage III/N2 non-small-cell lung cancer: a retrospective single-center cohort study’: [ESMO Open Volume 7, Issue 2, April 2022, 100466]
por: Sinn, K., et al.
Publicado: (2022)

Existing models, but not neutrophil-to-lymphocyte ratio, are prognostic in malignant mesothelioma
por: Meniawy, T M, et al.
Publicado: (2013)

Pleural Fluid Mesothelin as an Adjunct to the Diagnosis of Pleural Malignant Mesothelioma
por: Creaney, Jenette, et al.
Publicado: (2014)

Inhibin/activin expression in human and rodent liver: subunits α and βB as new players in human hepatocellular carcinoma?
por: Frost, K, et al.
Publicado: (2011)

Profile of soluble factors in pleural effusions predict prognosis in mesothelioma
por: Dick, I.M., et al.
Publicado: (2022)

Surgery for pleural mesothelioma, when it is indicated and why: arguments against surgery for malignant pleural mesothelioma
por: Woodard, Gavitt A., et al.
Publicado: (2020)

Calprotectin: a novel biomarker for the diagnosis of pleural effusion
por: Sánchez-Otero, N, et al.
Publicado: (2012)

Controversies in oncology: surgery for small cell lung cancer? It’s time to rethink the case
por: Hoda, Mir Alireza, et al.
Publicado: (2018)

Pleural fluid analysis of lung cancer vs benign inflammatory disease patients
por: Kremer, R, et al.
Publicado: (2010)

Induction of metallothionein expression by supplementation of zinc induces resistance against platinum-based treatment in malignant pleural mesothelioma
por: Wyrich, Martine, et al.
Publicado: (2023)

MDM2 is an important prognostic and predictive factor for platin–pemetrexed therapy in malignant pleural mesotheliomas and deregulation of P14/ARF (encoded by CDKN2A) seems to contribute to an MDM2-driven inactivation of P53
por: Walter, R F H, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_t6fj99taeuddsc3btqp78q64ec